Article Per Year (5 Year)
p-Index From 2020 - 2025
0.778
P-Index
This Author published in this journals
All Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research
Afriani Afriani
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Profile of Side Effects of Chemotherapy in Non-Small Cell Lung Cancer Patients (NSCLC) Undergoing Chemotherapy at Dr. M. Djamil General Hospital, Padang, Indonesia Isnaniyah Usman; Sabrina Ermayanti; Afriani Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 16 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i16.704

Abstract

Background: Chemotherapy is one of the treatment options for lung cancer at any stage. Side effects due to chemotherapy are still a problem in the treatment of lung cancer patients. Chemotherapy drugs have different side effects according to their pharmacokinetics and pharmacodynamics. This study aimed to determine the side effects of both hematological and non-hematological chemotherapy in non-small cell lung cancer patients treated at the lung ward of Dr. M. Djamil General Hospital, Padang, Indonesia, from 2017 to 2019. Methods: This was a descriptive observational study, a total of 42 study subjects. The study subjects were non-small cell lung cancer patients undergoing first-line chemotherapy. Sociodemographic, clinical, and laboratory data analysis was carried out with the help of SPSS software in a univariate manner. Results: The study subjects were mostly male (85.36%), the age range of 40-60 years (66.67%), at risk of exposure from work (45.23%), smokers (59.52%), had a history of pulmonary TB (11.9%), history of COPD (2.38%), history of malignancy of other organs (2.38%) with the most cell type being adenocarcinoma (54.76%). The most common hematological side effects were first-degree anemia (21.43%) and first-degree leukopenia (21.43%). The most non-hematological side effects were first-degree alopecia (90.48%), followed by first-degree nausea and vomiting (78.57%). Conclusion: Chemotherapy side effects were found in all regimens given with mild degrees. The side effects obtained were in the form of hematological and non-hematological side effects.
Profile of Side Effects of Chemotherapy in Non-Small Cell Lung Cancer Patients (NSCLC) Undergoing Chemotherapy at Dr. M. Djamil General Hospital, Padang, Indonesia Isnaniyah Usman; Sabrina Ermayanti; Afriani Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 16 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i16.704

Abstract

Background: Chemotherapy is one of the treatment options for lung cancer at any stage. Side effects due to chemotherapy are still a problem in the treatment of lung cancer patients. Chemotherapy drugs have different side effects according to their pharmacokinetics and pharmacodynamics. This study aimed to determine the side effects of both hematological and non-hematological chemotherapy in non-small cell lung cancer patients treated at the lung ward of Dr. M. Djamil General Hospital, Padang, Indonesia, from 2017 to 2019. Methods: This was a descriptive observational study, a total of 42 study subjects. The study subjects were non-small cell lung cancer patients undergoing first-line chemotherapy. Sociodemographic, clinical, and laboratory data analysis was carried out with the help of SPSS software in a univariate manner. Results: The study subjects were mostly male (85.36%), the age range of 40-60 years (66.67%), at risk of exposure from work (45.23%), smokers (59.52%), had a history of pulmonary TB (11.9%), history of COPD (2.38%), history of malignancy of other organs (2.38%) with the most cell type being adenocarcinoma (54.76%). The most common hematological side effects were first-degree anemia (21.43%) and first-degree leukopenia (21.43%). The most non-hematological side effects were first-degree alopecia (90.48%), followed by first-degree nausea and vomiting (78.57%). Conclusion: Chemotherapy side effects were found in all regimens given with mild degrees. The side effects obtained were in the form of hematological and non-hematological side effects.
Overview of Interleukin-6 Levels in COVID-19 (Coronavirus Disease 2019) Patients at Dr. M. Djamil General Hospital, Padang, Indonesia Adhika Rahman; Irvan Medison; Afriani Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 3 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i3.787

Abstract

Background: COVID-19 infection can cause an exaggerated immune response. This immune response is associated with an increase in proinflammatory cytokines, especially interleukin-6 (IL-6). High IL-6 levels are found in the acute stage of COVID-19, and IL-6 can induce an excessive humoral inflammatory response. This study aimed to provide an overview of IL-6 levels in coronavirus disease 2019 (COVID-19) patients at Dr. M. Djamil General Hospital, Padang, Indonesia. Methods: Descriptive observational study of 102 research subjects. Observations on sociodemographic, clinical, and laboratory data were carried out in this study. Univariate analysis was carried out using SPSS version 25. Results: Patients with symptom onset <7 days had higher IL-6 levels than those with an onset of more than 7 days. Patients with critical degrees have the highest IL-6 levels compared to moderate and severe degrees. Patients with more than 1 comorbid had higher IL-6 levels than patients who had no comorbid or only had 1 comorbid. Patients with <21 days of treatment had higher IL-6 levels than patients with more than 21 days of treatment. Conclusion: COVID-19 patients at Dr. M. Djamil General Hospital, Padang, Indonesia, with an onset of less than 7 days, a critical degree, and more than 1 comorbidity have higher IL-6 levels.
Overview of Interleukin-6 Levels in COVID-19 (Coronavirus Disease 2019) Patients at Dr. M. Djamil General Hospital, Padang, Indonesia Adhika Rahman; Irvan Medison; Afriani Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 3 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i3.787

Abstract

Background: COVID-19 infection can cause an exaggerated immune response. This immune response is associated with an increase in proinflammatory cytokines, especially interleukin-6 (IL-6). High IL-6 levels are found in the acute stage of COVID-19, and IL-6 can induce an excessive humoral inflammatory response. This study aimed to provide an overview of IL-6 levels in coronavirus disease 2019 (COVID-19) patients at Dr. M. Djamil General Hospital, Padang, Indonesia. Methods: Descriptive observational study of 102 research subjects. Observations on sociodemographic, clinical, and laboratory data were carried out in this study. Univariate analysis was carried out using SPSS version 25. Results: Patients with symptom onset <7 days had higher IL-6 levels than those with an onset of more than 7 days. Patients with critical degrees have the highest IL-6 levels compared to moderate and severe degrees. Patients with more than 1 comorbid had higher IL-6 levels than patients who had no comorbid or only had 1 comorbid. Patients with <21 days of treatment had higher IL-6 levels than patients with more than 21 days of treatment. Conclusion: COVID-19 patients at Dr. M. Djamil General Hospital, Padang, Indonesia, with an onset of less than 7 days, a critical degree, and more than 1 comorbidity have higher IL-6 levels.
Co-Authors Adhika Rahman Ermayanti, Sabrina Irvan Medison Isnaniyah Usman